[A13-26] Addendum to Commission A13-09 (vandetanib)
Last updated 05.09.2013
Project no.:
A13-26
Commission:
Commission awarded on 24.07.2013 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Note:
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decidess on the extent of the added benefit, thus completing the early benefit assessment
| Project no. | Title | Status |
|---|---|---|
| A13-09 | Vandetanib (second assessment) - Benefit assessment according to § 35a Social Code Book V (dossier assessment) | Commission completed |
Federal Joint Committee (G-BA)
2013-09-05 A G-BA decision was published.